Replies to post #238756 on Biotech Values

[DewDiligence]

ARDX—Meeting the clinical-trial endpoints does not ensure FDA approval. The phase-3 trials may have been overpowered to show statistical significance for a small effect size.

Isn’t the FDA involved in defining acceptable success criteria for trials?

Yes, to a degree. However, FDA feedback on clinical-trial design is not binding.